Trick or Treat: Trick your
Immune System and Turn off your Peanut Allergy
“We think we’ve found a way to safely and
rapidly turn off the allergic response to food allergies,”
says Paul Bryce, an
assistant professor at Northwester University
Anaphylaxis is the
body’s severe, allergic reaction to an allergen. It occurs
after the initial exposure to a foreign substance such as a peanut or bee sting
venom causes a body to become sensitized to that substance. On a second exposure to this foreign substance,
the body recognizes it as an allergen triggering an adverse reaction, which can
result in anaphylaxis. Typically within 15 to 30 minutes of exposure, the
body undergoes a severe reaction. Some
of the symptoms include throat
swelling, an itchy rash, low blood pressure and/or shock which
can eventually lead to loss of consciousness and death. During
anaphylaxis, tissues from different parts of the body release histamine and other cytokines
that can cause the airways to tighten the throat to close. According to the National
Institutes of Health (NIH), approximately 15,000
to 30,000 episodes of anaphylaxis and 100 to 200 related deaths occur each
year within the United States.
From an immunological perspective, anaphylaxis is
classified as a type 1 hypersensitivity. In type 1 hypersensitivity,
an antigen producing cell (APC) presents an
antigen to a CD4+ Th2 cell which stimulates B cell proliferation,
differentiation and production of IgE
antibodies specific to the antigen. The IgE antibodies bind to Fc receptors on the
surface of mast cells and basophils.
These coated cells are termed
“sensitized” by the IgE. When the body is exposed to the same allergen another
time, the bound IgE on these sensitized cells cross-link. This interaction
signals the release of active mediators of inflammations such as histamine, leukotriene, and prostaglandin to the
surrounding tissues which leads to anaphylaxis.
All of
this research raises the question of why do some people develop
hypersensitivity while others do not? The
exact mechanism as to why some individuals are more prone to type-I hypersensitivity
is not fully understood. However, previous research has shown that individuals
with this form of sensitivity produce more TH2 cells that secrete IL-4, IL-5
and IL-13 which promote isotype switching to the IgE production observed in
this allergic response.
For highly allergic individuals,
even the smallest amount of allergen can provoke anaphylaxis. Currently avoidance and symptom control are the
most widely used means to cope with most allergies. Therefore in his study titled Antigen-Fixed Leukocytes Tolerize Th2 Responses in
Mouse Models of Allergy, Smarr
and his team of researchers attempted to find a more pragmatic cure for
allergies. In previous research
projects, Smarr’s team has demonstrated
that intravenous administration of peptides attached to the surface of
syngeneic splenic leukocytes termed Ag-coupled splenocytes (Ag-SPs)
with the chemical crosslinking agent 1-ethyl-3-(39-dimethylaminopropyl)-carbodimide (ECDI) safely and
efficiently induced Ag-specific immune tolerance. This enabled the team to attach an antigen
the hypersensitive person would normally recognize as foreign and attack, such
as antigens from peanuts, to white blood cells called leukocytes. When these modified white blood cells were
reintroduced into the individual the individual would not experience the
life-threatening allergic reaction because their immune system now recognizes
the antigen as safe. Their previous success with this model in autoimmune
studies with TH1/Th17 mediated models encouraged them to extend their
work with this model to study Th2 models associated with food allergies.
In
this study, Smarr et al 2011 pretreated mice with ECDI-fixed Ag-coupled splenocytes
in two murine models: a food allergy model to whole peanut extract (WPE) and an Ovalbumin-induced
(OVA-induced) allergic asthma airway
inflammation model to examine the effectiveness of Ag-SP–induced tolerance to control
allergic reactions. These models therefore mimicked an allergic asthma
and an allergic peanut food allergy response in mice respectively.
In the
allergic airway inflammation model, they administered OVA-coupled splenocytes
(OVA-SP) into pre-sensitized mice before two exposures with OVA in alum
adjuvant. They compared the effect of the OVA-SP to Sham-SP (MBP-SP) on local
allergic responses induced by the inhaled allergen, aerosolized OVA. After
examining the Bronchoalveolar lavage (BAL)
fluid, they determined that the OVA-SP treated mice had significantly reduced
lung esinophilia as well as reduced Th2-associated cytokines IL-4 and IL-5. Furthermore, the allergic response was
inhibited which was indicated by the reduced concentrations of blood eosinophils as well
as reduced OVA-specific IgE levels.
In the food allergy model (WPE), the
researchers constructed Ag-SPs by attaching peanut proteins onto white blood
cells called leukocytes. They reintroduced these modified leukocytes into the
mice prior to sensitization. After two
treatments, the mice were fed a peanut extract. Fifteen minutes after
digestion, the mice tolerized with WPE showed significantly reduced symptom
scores compared to the control Sham-SP tolerized mice. Tolerization occurs when
allergens rendered nonimmunogenic are used to stimulate
formation of allergen-specific suppressor T lymphocytes that will suppress IgE
synthesis. The core
body temperature was also measured because anaphylaxis is known to lead to
vascular leaks and hypothermia because of hypotension which can
lead to decreases in body temperature. They found that the WPE-Sps significantly prevented
core temperature decreases. Peripheral blood esopsinophil numbers were also
reduced. Furthermore WPE-specific IgE
was undetectable whereas the WPE-specific IgG1 was unaffected. The results
suggested that WPE treated mice prevented the Ag-specific Th2 associated allergic
response. The treated mice also showed extremely reduced or absent levels of
anaphylaxis, which led Smarr’s team to conclude that the mice’s immune system
now recognized the protein as safe and therefore restrained from mounting an
immune response.
The
authors’ work shows that the Ag-SP method efficiently, quickly and safely
prevented allergic disease responses in mice.
Ag-SP in both models decreased Th2 responses, eosophilia and Ag-Specific
IgE. The success of the project has led
the authors to want to extend their work in the future to perhaps attaching
more than one protein to the surface of white blood cells to see if they can
target multiple allergies at once. They
also have extended this model to other fields of concern in immunology such as
autoimmune diseases like rheumatoid arthritis and type I diabetes. Other researchers at Northwestern University
are currently using a similar technique to study the progression of multiple
sclerosis. Hopefully this model that appears to be successful in murine models
will be equally successful in humans. Maybe one day peanut allergies and asthma
will be a thing of the past.
Source
Smarr CB, Hsu CL, Byrne AJ, Miller SD, Bryce PJ. (2011). Antigen-Fixed Leukocytes Tolerize Th2 Responses in Mouse Models of
Allergy. J Immunol.
Other
Sources
Anaphylaxis . NIH (2010). Retrieved on October 16, 2011
from http://www.ncbi.nlm.nih.gov/pubmedhealt/PMH0001847/
Ghaffar, Abdul. IMMUNOLOGY -
CHAPTER SEVENTEEN HYPERSENSITIVITY REACTIONS. Retrieved on October 16th 2011 from http://pathmicro.med.sc.edu/ghaffar/hyper00.htm.
How have they used this model to look at type I diabetes thus far?
ReplyDeleteThis was a very interesting article. My son has a ton of allergies. I am always worried about leaving him at home with a babysitter when she might not be watching as carefully. Hopefully they will be able to integrate this clinically.
ReplyDeleteThis was really interesting. I have never heard of this mechanism of tolerizing models to test immune responses. Do they plan to conduct the experiment with larger mammals? or an animal more closely related to people?
ReplyDeleteNicely done Addie!
ReplyDeleteHow will they use the model to study diseases that aren't related to allergies/allergens? I never really thought of allergies as being closely associated with the immune system. Could a study like this apply to allergies that are pretty widespread among people like poision ivy (or poison sumac!)
I have never heard of this method before. It sounds very promising. Can they use it for outdoor allergens as well. Is there a way to introduce the cells back in the body with out ivs?
ReplyDeleteWow! I hope this goes to a clinical trial. What does the BAL fluid tell them exactly?
ReplyDeleteHave you studied this during your immunology course? I was wondering if it is a well known method or just in the beginning stages. Also what does it mean to have decreased TH2 responses?
ReplyDelete